Cost of disorders of the brain in Europe 2010 A Gustavsson, M Svensson, F Jacobi, C Allgulander, J Alonso, E Beghi, ... European neuropsychopharmacology 21 (10), 718-779, 2011 | 2232 | 2011 |
Resources for mental health: scarcity, inequity, and inefficiency S Saxena, G Thornicroft, M Knapp, H Whiteford The lancet 370 (9590), 878-889, 2007 | 2093 | 2007 |
Defeating Alzheimer's disease and other dementias: a priority for European science and society B Winblad, P Amouyel, S Andrieu, C Ballard, C Brayne, H Brodaty, ... The Lancet Neurology 15 (5), 455-532, 2016 | 1817 | 2016 |
Costs of autism spectrum disorders in the United Kingdom and the United States AVS Buescher, Z Cidav, M Knapp, DS Mandell JAMA pediatrics 168 (8), 721-728, 2014 | 1773 | 2014 |
Social isolation, loneliness and health in old age: a scoping review E Courtin, M Knapp Health & social care in the community 25 (3), 799-812, 2017 | 1453 | 2017 |
Costing psychiatric interventions J Beecham, M Knapp Measuring mental health needs 2, 200-224, 2001 | 1444 | 2001 |
Financial cost of social exclusion: follow up study of antisocial children into adulthood S Scott, M Knapp, J Henderson, B Maughan Bmj 323 (7306), 191, 2001 | 1388 | 2001 |
World Alzheimer Report 2016. Improving healthcare for people living with dementia: Coverage, Quality and costs now and in the future. M Prince, A Comas-Herrera, M Knapp, M Guerchet, M Karagiannidou Alzheimer's Disease International, 2016 | 1359 | 2016 |
Poverty and mental disorders: breaking the cycle in low-income and middle-income countries C Lund, M De Silva, S Plagerson, S Cooper, D Chisholm, J Das, M Knapp, ... The lancet 378 (9801), 1502-1514, 2011 | 1049 | 2011 |
Donepezil and memantine for moderate-to-severe Alzheimer's disease R Howard, R McShane, J Lindesay, C Ritchie, A Baldwin, R Barber, ... New England Journal of Medicine 366 (10), 893-903, 2012 | 917 | 2012 |
The effectiveness of supported employment for people with severe mental illness: a randomised controlled trial T Burns, J Catty, T Becker, RE Drake, A Fioritti, M Knapp, C Lauber, ... The Lancet 370 (9593), 1146-1152, 2007 | 887 | 2007 |
Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology DS Baldwin, IM Anderson, DJ Nutt, B Bandelow, A Bond, JRT Davidson, ... Journal of Psychopharmacology 19 (6), 567-596, 2005 | 853* | 2005 |
The global costs of schizophrenia M Knapp, R Mangalore, J Simon Schizophrenia bulletin 30 (2), 279-293, 2004 | 768 | 2004 |
The Clinical Global Impression–Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia JM Haro, SA Kamath, SO Ochoa, D Novick, K Rele, A Fargas, ... Acta Psychiatrica Scandinavica 107, 16-23, 2003 | 753 | 2003 |
Effect of telehealth on use of secondary care and mortality: findings from the Whole System Demonstrator cluster randomised trial A Steventon, M Bardsley, J Billings, J Dixon, H Doll, S Hirani, M Cartwright, ... Bmj 344, 2012 | 739 | 2012 |
Projections of multi-morbidity in the older population in England to 2035: estimates from the Population Ageing and Care Simulation (PACSim) model A Kingston, L Robinson, H Booth, M Knapp, C Jagger, Modem Project Age and ageing 47 (3), 374-380, 2018 | 734 | 2018 |
Dementia UK: update M Prince, M Knapp, M Guerchet, P McCrone, M Prina, A Comas-Herrera, ... King's College London, 2014 | 711 | 2014 |
Measurement of health-related quality of life for people with dementia: development of a new instrument (DEMQOL) and an evaluation of current methodology. SC Smith, DL Lamping, S Banerjee, R Harwood, B Foley, P Smith, ... Health Technology Assessment (Winchester, England) 9 (10), 1-iv, 2005 | 709 | 2005 |
Long-term conditions and mental health: the cost of co-morbidities C Naylor, M Parsonage, D McDaid, M Knapp, M Fossey, A Galea King’s Fund (London, England), 2012 | 696 | 2012 |
Mental health promotion and mental illness prevention: The economic case M Knapp, D McDaid, M Parsonage Department of Health, 2011 | 653 | 2011 |